For the quarter ended February 2026, Neogen (NEOG Quick QuoteNEOG - Free Report) reported revenue of $211.2 million, down 4.4% over the same period last year. EPS came in at $0.09, compared to $0.10 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $204.46 million, representing a surprise of +3.3%. The company delivered an EPS surprise of +125%, with the consensus EPS estimate being $0.04.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Neogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Animal Safety: $54.5 million versus the three-analyst average estimate of $56.02 million. The reported number represents a year-over-year change of -20.2%.
• Revenues- Food Safety: $156.7 million compared to the $148.11 million average estimate based on three analysts. The reported number represents a change of +2.6% year over year.
• Revenues- Food Safety- Indicator Testing, Culture Media & Other: $83 million versus the two-analyst average estimate of $81.18 million. The reported number represents a year-over-year change of +6.8%.
• Revenues- Animal Safety- Life Sciences: $1.5 million versus the two-analyst average estimate of $1.55 million. The reported number represents a year-over-year change of -0.3%.
• Revenues- Animal Safety- Veterinary Instruments & Disposables: $15.5 million versus $15.38 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +0.6% change.
• Revenues- Animal Safety- Animal Care & Other: $5.9 million versus the two-analyst average estimate of $9.61 million. The reported number represents a year-over-year change of -43.8%.
• Revenues- Food Safety- Natural Toxins & Allergens: $17.9 million versus the two-analyst average estimate of $17.65 million. The reported number represents a year-over-year change of +1.7%.
• Revenues- Animal Safety- Genomics Services: $16.6 million versus the two-analyst average estimate of $3.34 million. The reported number represents a year-over-year change of -2.4%.
• Revenues- Food Safety- Genomics Services: $6.2 million compared to the $11.34 million average estimate based on two analysts. The reported number represents a change of +8.9% year over year.
• Revenues- Food Safety- Biosecurity Products: $3.9 million versus the two-analyst average estimate of $4.29 million. The reported number represents a year-over-year change of -67%.
• Revenues- Food Safety- Bacterial & General Sanitation: $42.1 million versus $40.39 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.
• Revenues- Animal Safety- Biosecurity Products: $15 million compared to the $18.96 million average estimate based on two analysts. The reported number represents a change of -37.1% year over year.

View all Key Company Metrics for Neogen here>>>

Shares of Neogen have returned +4.9% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.